Future Outlook of the Plasma Protein Therapeutics Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the plasma protein therapeutics market right now?
There has been a significant expansion in the size of the plasma protein therapeutics market in the recent past. The market, valued at $31.86 billion in 2024, is poised to reach $34.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.5%. Factors contributing to its growth during the previous years include the rising incidence of rare diseases, an increase in the elderly population, an ample supply of blood plasma globally, a surge in hemophilia cases, advancements in diagnostic methods, and supportive regulatory landscape.
How fast Is the plasma protein therapeutics market expected to grow, and what’s its future value?
Projected to experience robust growth in the coming years, the market size for plasma protein therapeutics is expected to reach $46.35 billion in 2029, progressing at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during the forecast period is primarily driven by advancements in gene therapy, heightened healthcare spending, the expansion of indications, precision medicine techniques, and patient access programs. Key predicted trends for the forecast period encompass technological breakthroughs, the incorporation of telemedicine, progressive advancements in plasma fractionation technology, the generation of next-level therapies, the application of recombinant therapies, and personalized medicine strategies.
Get your plasma protein therapeutics market report here!
https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report
What are the leading drivers of growth in the plasma protein therapeutics market?
The plasma protein therapeutics market’s expansion is anticipated to be driven by a growing occurrence of autoimmune diseases. A condition where the body’s immune system targets and eradicates healthy cells is known as an autoimmune disease. Therapeutic plasma exchange, used in treating these diseases, occurs when the body falsely identifies a part of itself as foreign, producing proteins (known as autoantibodies) that attack the wrongly identified body part. In May 2023, a research involving 22 million people by the University of Glasgow, a public university in the UK, revealed that autoimmune diseases affect around 10% of the UK population, surpassing previous estimates. Consequently, the rising occurrence of autoimmune diseases is fuelling the growth of the plasma protein therapeutics market in the future.
What are the key segments defining the plasma protein therapeutics market?
The plasma protein therapeutics market covered in this report is segmented –
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications
Subsegments:
1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
2) By Albumin: Human Serum Albumin, Recombinant Albumin
3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates
4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors
5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp
Who are the key players steering the development of the plasma protein therapeutics market?
Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood
What emerging trends are influencing the growth of the plasma protein therapeutics market?
One notable trend gaining traction in the plasma protein therapeutic market is product innovation. Many large-scale enterprises in this field are zeroing in on pioneering products as a way to establish their market dominance. An apt illustration of this is Octapharma AG, a company based in Switzerland that in October 2023 received authorization from European health regulators for the freeze-dried variant of its acclaimed product, octaplasLG. Conceived for pre-hospital transfusion, this evolved formulation gives healthcare providers an accessible and potent solution for treating critically ill patients. The granted approval highlights Octapharma’s dedication towards improving patient care by offering innovative blood product solutions.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9213
Which regions are most influential in expanding the plasma protein therapeutics market?
North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Blood Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Rituximab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report
Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
